Search

The May 20 installment of “MSK Science Spotlight” will feature guest speaker, Katherine High, MD, Professor Emerita, Perelman School of Medicine of the University of Pennsylvania; Co-founder and former President and Head of R&D, Spark Therapeutics.

… Wednesday, May 20, 2020 MSK Science Spotlight The May 20 installment of “ MSK Science Spotlight ” will feature guest speaker, Katherine High, MD, Professor Emerita, Perelman School of Medicine of the University of Pennsylvania; Co-founder and former President and Head of R&D, Spark Therapeutics. Hosted

A team of researchers led by Memorial Sloan Kettering immunologist Alexander Rudensky has gained new understanding about regulatory T cells -- a subtype of immune cells that suppresses the immune system's reactivity.

… Saturday, January 1, 2011 Summary A team of researchers led by Memorial Sloan Kettering immunologist Alexander Rudensky has gained new understanding about regulatory T cells — a subtype of immune cells that suppresses the immune system’s reactivity. A team of researchers led by Memorial Sloan Kettering

Every year, the Gerstner Sloan Kettering Graduate School of Biomedical Sciences recognizes student research with fellowship awards based on academic excellence.

… Tuesday, September 18, 2018 Summary The Gerstner Sloan Kettering Graduate School of Biomedical Sciences has awarded fellowships to two third-year students and six second-year students through the annual Grayer Fellowships, the Olayan Fellowship, the Robert B. Catell Fellowship, the Palestin Fellowship

Meet Nikki Gioia, who treated for Hodgkin lymphoma at MSK and is now an MSK nurse.

… Wednesday, May 9, 2018 Summary This story originally appeared in Bridges, MSK’s newsletter for cancer survivors. Bridges offers a forum in which patients and their families can share stories of inspiration and hope, and of the challenges that can accompany a cancer journey. Learn more about how to receive

Discover how a watch-and-wait approach to treating rectal cancer can help people avoid surgery and preserve normal body functions.

… Tuesday, January 15, 2019 Summary The biggest study of its kind in North America finds a watch-and-wait strategy can have excellent long-term results for some people with rectal cancer. Cancers of the colon and rectum are often grouped together as colorectal cancer because both are part of the large

With the help of machine learning, computational biologists are learning to predict how cancers will evolve.

… Wednesday, June 23, 2021 From amoebas to zebras, all living things evolve. They change over time as pressures from the environment cause individuals with certain traits to become more common in a population while those with other traits become less common. Cancer is no different. Within a growing tumor

Learn about gastrointestinal distress, one of the more common side effects of immunotherapy.

… Thursday, January 31, 2019 Summary One of the most common immunotherapy side effects is gastrointestinal distress. MSK gastroenterologist David Faleck explains why this happens and how to find relief. Chances are that you have heard some buzz about immunotherapy . This type of cancer treatment trains

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Michel Sadelain, MD, PhD, renowned physician-scientist, Director of the Center for Cell Engineering, and Stephen and Barbara Friedman Chair, has been awarded the 2024 Breakthrough Prize in Life Sciences.

… Thursday, September 14, 2023 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Michel Sadelain, MD, PhD, renowned physician-scientist, Director of the Center for Cell Engineering, and Stephen and Barbara Friedman Chair, has been awarded the 2024  Breakthrough Prize in Life Sciences

Bevacizumab (Avastin®) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer, according to a new study. Results from the phase III "OCEANS" trial were presented today by the lead author, Carol Aghajanian, MD, of Memorial Sloan Kettering Cancer Center, at the 2011 annual meeting of the American Society of Clinical Oncology.

… Saturday, June 4, 2011 Bevacizumab (Avastin®) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer , according to a new study. Results from the phase III “OCEANS” trial were presented today by the lead author, Carol Aghajanian, MD , of Memorial Sloan

Today Memorial Sloan Kettering (MSK) announced the appointment of a task force that will assess MSK policies and processes for reporting and managing outside activities and industry-supported clinical trials.

… Friday, September 21, 2018 Today Memorial Sloan Kettering (MSK) announced the appointment of a task force that will assess MSK policies and processes for reporting and managing outside activities and industry-supported clinical trials. The task force was announced in a statement from MSK President and